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 Here is the second, revised and enlarged edi-
tion of the book on autoimmune skin diseases, 
written by 36 authors from Europe, USA, Japan 
and Israel. Editor of the first and second edition 
is Dr. Michael Hertl from Marburg, who dedicated 
the second edition to his teacher, Professor Gerd-
Klaus Staigleder, on the occasion of his 80th birth-
day. 
 The first, introductory chapter provides an over-
view of the latest concepts on the pathogenesis 
of autoimmune diseases and the phenomenon of 
autoimmunity in general. This complex issue is 
clearly and concisely presented, making it very 
convenient for the reader by three excellent sche-
matic presentations. A total of 106 mostly recent 
references are listed at the end of the section. It 
should be noted that all chapters of the book are 
accompanied by a hundred or more references. 
Second chapter deals with the epidemiology of 
autoimmune diseases. The authors stress that 
epidemiology is an important science that might 
lead to relevant information on the frequency of 
autoimmune diseases and the risk factors associ-
ated with the disease, thus allowing appropriate 
distribution of health care resources and planning 
of preventive mesaures.
 The chapter on bullous autoimmune diseases 
of the skin provides latest data on the etiopatho-
genesis of pemphigus, with special reference to 
autoantibody reactivity against desmogleins. The 
chapter is accompanied by a very convenient and 
clear table listing autoantigens in various forms of 
pemphigus. This is continued by a review of ani-
mal models for the study of pemphigus, with spe-
cial reference to desmoglein 3-deficient mouse 
model. Mention is made of all known clinical vari-
ants of pemphigus, and some novel possibilities 
for an early diagnosis of pemphigus are highlight-
ed. Immunoblot and ELISA analysis of pemphigus 
sera provides a unique possibility to establish the 
diagnosis of pemphigus even without histology 
and direct immunofluorescence of skin biopsy. 
Some new adjuvant therapies such as immuno-
adsorption therapy are described. Adsorbents 
(protein A, tryptophan, phenylalanine, and dextran 
sulfate as ligands) have been introduced in clini-
cal use. These adsorbents remove their targets 
through hydrophobic binding. The most important 
advantages of immunoadsorption over unselected 
plasmapheresis include higher selectivity in the 
removal of pathogens, reduced loss of essential 
plasma components, and no requirement of pro-
tein replacement with all its risks.
 The chapter on bullous pemphigoid contains 
highly convenient schematic presentations. It is 
clear that patient’s autoantibodies are directed 
against bullous pemphigoid antigens 230 and 
180. These two autoantigens are components of 
hemidesmosomes, adhesion complexes in human 
skin that promote dermoepidermal cohesion.
 The review of bullous dermatoses offers re-
cent data on dermatitis herpetiformis, enriched by 
high-quality immunofluorescence photographs. 
Epidermolysis bullosa acquisita is an extensively 
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described clinical entity. Therapeutic options for 
this dermatosis include colchicine, immunosup-
pressants, intravenous immunoglobulins, photo-
pheresis, and immunoadsorption.
 Fourth chapter of the book tackles scleroder-
ma, i.e. both localized and progressive systemic 
scleroderma, with special attention paid to the lat-
ter. Despite intense research efforts and major ad-
vances in the understanding of particular aspects 
of the disease process, the etiology of systemic 
scleroderma remains unknown while its pathogen-
esis is only partly understood. 
 The chapter on erythematous skin disorders, a 
thorough account is given of chronic discoid lupus 
erythematosus, subacute and systemic lupus ery-
thematosus. Thalidomide is mentioned as a thera-
peutic modality in systemic treatment of subacute 
lupus erythematosus.
 Dermatomyositis is extensively described. 
Dermatomyositis in adults is associated with ma-
lignancy, thus careful evaluation of each patient 
should be part of the initial and follow-up assess-
ments. 
The chapter on mixed connective tissue disease 
describes it as a rather well defined group of dis-
eases with a characteristic mixed clinical picture 
of several connective tissue diseases and autoan-
tibody to U1snRNP. This is continued by thorough 
description of Sjögren’s syndrome. The condition 
may exist as a primary entity or in association with 
other autoimmune disorders such as systemic 
lupus erythematosus, dermatomyositis, sclero-
derma, etc. 
 The chapter on psoriasis has been written by 
J.C. Prinz. He concludes that psoriasis has only 
gained acceptance as a T cell mediated disorder. 
Therefore, its presentation in a book on autoim-
munity may still raise objections. At closer sight, 
however, psoriasis meets many criteria for auto-
immune disease: it has a genetic background with 
a strong HLA-class I association; microbial infec-
tion contributes to the disease onset; and T cells 
apparently play an essential role in the disease 
manifestation. Yet, only the identification of the 
putative autoantigens will definitely prove its auto-
immune nature.
 Chronic urticaria as an autoimmune disease is 
described in detail in the tenth chapter of the book. 
Between 30 and 50 per cent of patients with au-
toimmune chronic urticaria have IgG autoantibod-
ies directed against alpha-chain of the high-affinity 
IgE receptor (FcRIα) expressed on dermal mast 
cells or on blood basophils. 
 
 The chapter on lichen planus, lichenoid erup-
tions and cutaneous graft-versus-host reaction 
delineates some of the recent aspects of the etio-
pathogenesis, clinical manifestations and tretment 
modalities. 
 Small vessel vasculitides affecting the skin are 
seen in primary systemic vasculitides, i.e. ANCA-
associated vasculitides (Wegener's granulomato-
sis, MPA-microscopic polyangiitis) and immune 
complex-mediated vasculitides (cryoglobulinemic 
vasculitis, HSP, CLA). Secondary immune com-
plex-mediated, e.g., in SLE and other connective 
tissue diseases, paraneoplastic conditions and 
infectious diseases also frequently involve small 
vessels of the skin. Diagnosis is based on detailed 
patient history, physical examination, focused lab-
oratory investigation, and demonstration of vascu-
litis by biopsy.
 The present, second edition of the book for the 
first time addresses vitiligo and alopecia areata 
from the aspect of autoimmune diseases. Criti-
cal analysis is given of the hypotheses raised to 
date on the pathogenesis of vitiligo. While auto-
immunity still is the favored hypothesis on vitiligo, 
the evidence collected to date do not support the 
idea that vitiligo belongs to the group of primary 
autoimmune diseases. In case of alopecia areata, 
a rodent model study has shown that it is an im-
mune mediated disease, strongly suggesting that 
the mechanism is autoimmune in nature. It is like-
ly that alopecia areata susceptibility and severity 
modifyng genes are primarily involved in the im-
mune system, while other susceptibility genes may 
control hair follicle function. The authors conclude 
that they still cannot claim alopecia areata as an 
autoimmune disease with complete evidence, yet 
all evidence produced so far point in this direction 
and strongly support the hypothesis.
 The last chapter is dedicated to novel thera-
peutic procedures for autoimmune diseases. Men-
tion is made of many new immunomodulators (im-
munosuppressant macrolides, leflunomide, and 
antigen specific approach in the management of 
autoimmune diseases, therapeutic options with 
the use of autoantigens, antigen modification 
to induce tolerance, modification of the effector 
stage of autoimmune diseases via inhibition of 
tumor necrosis factor α synthesis). The concept 
of immunoadsorption is explained. The reader's 
attention is drawn to the use of high doses of in-
travenous immunoglobulins as a therapeutic op-
tion in the treatment of autoimmune diseases. The 
chapter is closed by a review of biologicals. They 
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represent a new group of substances including 
monoclonal antibodies, fusion and recombinant 
proteins possessing biological activity. In the past 
years, a major progress has been made in the 
understanding of etiologic and pathogenetic fac-
tors involved in the pathogenesis of human auto-
immune diseases. Nevertheless, the majority od 
autoimmune diseases including those of the skin 
remain an enigma. This book provides latest in-
formation on the spectrum of cutaneous autoim-
mune disorders for many clinicians and scientists, 
parctitioners in dermatology, rheumatology, inter-
nal medicine, otorhinolaryngology, and pediatrics. 
                                          Aida Pašić, MD, PhD 
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Your skin needs Nivea cream to look young and well-cared for.
From the Nivea collection of Zlatko Puntijar (1936) 
